Back to top
more

Seres Therapeutics (MCRB)

(Delayed Data from NSDQ)

$1.14 USD

1.14
3,587,781

+0.07 (6.54%)

Updated Jun 5, 2024 04:00 PM ET

Pre-Market: $1.14 0.00 (0.00%) 8:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MCRB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Seres Therapeutics, Inc. [MCRB]

Reports for Purchase

Showing records 21 - 36 ( 36 total )

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/11/2020

Company Report

Pages: 5

Bold Action Culminates in a Positive SER-109 Phase 3 Readout; Reiterate Buy and Raising PT to $41

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

05/11/2020

Company Report

Pages: 5

Fortune Favors the Bold as SER-109 Accelerates its Advance; Reiterate Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

03/23/2020

Company Report

Pages: 5

We Look for Readouts in 2020 to Reaffirm the Safety of Seres.

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

11/21/2019

Company Report

Pages: 5

High Priority Programs Continue Their Advance to Important Catalysts in 2020; Reiterate Buy Rating and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

08/19/2019

Company Report

Pages: 5

Clinical Programs Make Solid 2Q19 Progress but are Flying Under the Radar; Reiterate Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

05/03/2019

Company Report

Pages: 5

1Q19 Results Reflect Headwinds to ECOSPOR III Persist but Costs Streamlined; Reiterating Buy and Adjusting PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

03/12/2019

Company Report

Pages: 4

AstraZeneca Collaboration Further Confirms Seres? Leadership in Potential Applications of the Microbiome in Oncology

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

03/11/2019

Company Report

Pages: 5

Lowering our PT to $13 but Remaining Positive That ECOSPOR III Prevails Against Headwinds in Patient Enrollment

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

02/22/2019

Company Report

Pages: 26

A Healthy Dose to the Gut Microbiome; Assuming Coverage With a Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 75.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/04/2017

Company Report

Pages: 7

SER-287 Phase 1B Trial Results in Ulcerative Colitis Patients Expected in 2H17; PT Raised to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 25.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

08/01/2016

Company Report

Pages: 6

Disappointing SER-109 Phase 2 Results; Reducing Price Target to $15 from $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 25.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

07/29/2016

Company Report

Pages: 32

Good Microbes Can Conquer Disease; Assuming Coverage With a $50 12-Month Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 75.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

04/28/2016

Industry Report

Pages: 5

Outlook on Microbiome Medicine, Part II

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

02/26/2016

Company Report

Pages: 6

Microbiome Restoration Pills Make Headway in CDI and UC; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

02/22/2016

Industry Report

Pages: 5

Outlook on Microbiome Medicine: Part I

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Seres Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

01/25/2016

Company Report

Pages: 28

Restoring Order to Unruly Microbiota; Initiating with a Buy Rating and $55 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 75.00

Research Provided by a Third Party